全文获取类型
收费全文 | 1130篇 |
免费 | 112篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 10篇 |
儿科学 | 69篇 |
妇产科学 | 24篇 |
基础医学 | 151篇 |
口腔科学 | 27篇 |
临床医学 | 133篇 |
内科学 | 317篇 |
皮肤病学 | 31篇 |
神经病学 | 111篇 |
特种医学 | 103篇 |
外科学 | 85篇 |
综合类 | 23篇 |
预防医学 | 50篇 |
眼科学 | 5篇 |
药学 | 55篇 |
肿瘤学 | 53篇 |
出版年
2023年 | 9篇 |
2022年 | 7篇 |
2021年 | 21篇 |
2020年 | 14篇 |
2019年 | 31篇 |
2018年 | 27篇 |
2017年 | 11篇 |
2016年 | 23篇 |
2015年 | 26篇 |
2014年 | 31篇 |
2013年 | 36篇 |
2012年 | 41篇 |
2011年 | 52篇 |
2010年 | 64篇 |
2009年 | 47篇 |
2008年 | 49篇 |
2007年 | 49篇 |
2006年 | 37篇 |
2005年 | 41篇 |
2004年 | 31篇 |
2003年 | 37篇 |
2002年 | 32篇 |
2001年 | 26篇 |
2000年 | 28篇 |
1999年 | 26篇 |
1998年 | 32篇 |
1997年 | 38篇 |
1996年 | 38篇 |
1995年 | 32篇 |
1994年 | 24篇 |
1993年 | 20篇 |
1992年 | 12篇 |
1991年 | 14篇 |
1990年 | 13篇 |
1989年 | 20篇 |
1988年 | 21篇 |
1987年 | 24篇 |
1986年 | 16篇 |
1985年 | 13篇 |
1984年 | 6篇 |
1983年 | 12篇 |
1982年 | 9篇 |
1981年 | 11篇 |
1979年 | 15篇 |
1978年 | 6篇 |
1977年 | 10篇 |
1976年 | 7篇 |
1974年 | 8篇 |
1971年 | 7篇 |
1970年 | 8篇 |
排序方式: 共有1247条查询结果,搜索用时 31 毫秒
61.
Breast cancer is the most common cause of cancer death in women in this country. Until recently, the traditional treatment has been radical surgery with or without radiation therapy for patients with primary breast cancer, and palliative endocrine therapy followed by chemotherapy for patients with advanced disease. These treatments have met with limited effectiveness in terms of eradicating the disease. Studies in the past decade have given cause for optimism for breast cancer patients. Adjuvant systemic therapy after local treatment appears promising for certain subsets of patients with primary breast cancer. The development of estrogen receptor assays has markedly changed our approach to the disease and improved patient care. Estrogen receptor is an important prognostic factor and is useful in planning appropriate therapy for patients with primary breast cancer as well as those with advanced disease. Further research is urgently needed to improve the dismal survival of certain women with this common malignancy. 相似文献
62.
63.
Carlo Dufour Marta Pillon Jakob Passweg Gerard Socié Andrea Bacigalupo Genny Franceschetto Elisa Carraro Rosi Oneto Antonio Maria Risitano Regis Peffault de Latour André Tichelli Alicia Rovo Christina Peters Britta Hoechsmann Sujith Samarasinghe Austin G Kulasekararaj Hubert Schrezenmeier Mahmoud Aljurf Judith Marsh 《Haematologica》2014,99(10):1574-1581
We analyzed the outcome of 537 adolescents (age 12–18 years) with idiopathic aplastic anemia included in the database of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation comparing: i) matched family donor hematopoietic stem cell transplantation performed as first-line treatment with ii) front-line immunosuppressive therapy not followed by subsequent transplant given for failure and with iii) hematopoietic stem cell transplantation performed after failed front-line immunosuppressive therapy. Overall survival was 86% in the matched family donor hematopoietic stem cell transplantation group, 90% in patients given front-line immunosuppressive alone (those who did not fail this treatment and who did not receive subsequent rescue with hematopoietic stem cell transplantation) and 78% in subjects who underwent hematopoietic stem cell transplantation post failed front-line immunosuppressive therapy (P=0.14). Event-free survival in the same groups was respectively 83%, 64% and 71% (P=0.04). Cumulative incidence of rejection was 8% in matched family donor hematopoietic stem cell transplantation and 9% in transplants post failed front-line immunosuppression (P=0.62). Cumulative incidence of acute graft-versus-host disease was 12% in matched family donor transplants and 18% in transplants post failed immunosuppression (P=0.18). Chronic graft-versus-host disease was higher in matched family donor hematopoietic stem cell transplantation (8%) than in transplants post failed immunosuppressive therapy (20%) (P=0.0009). Cumulative incidence of post-therapy malignancies was 0.7% in matched family donor transplantations, 7% in transplantations post failed immunosuppression and 21% after front-line immunosuppression (P=0.0017). In the whole cohort, under multivariate analysis, the diagnosis to treatment interval of two months or under positively affected overall survival whereas up-front immunosuppression alone (with no subsequent rescue transplants) negatively affected event-free survival. In transplanted patients an interval from diagnosis to treatment of 2 months or under, bone marrow as source of cells and first-line matched family donor transplants provided a significant advantage in overall and event-free survival. Aplastic anemia in adolescents has a very good outcome. If a matched family donor is available, hematopoietic stem cell transplantation using bone marrow cells is the first choice treatment. If such a donor is not available, immunosuppressive treatment may still be an acceptable second choice, also because, in case of failure, hematopoietic stem cell transplantation is a very good rescue option. 相似文献
64.
65.
66.
67.
68.
69.
70.
A Ascari‐Raccagni A Dondas MG Righini G Trevisan 《Journal of the European Academy of Dermatology and Venereology》2010,24(8):926-929
Background The repair of an alar nasal defect is a frequent challenge for dermatologic surgeons for reasons of the high rate of non‐melanoma cancers in the area. Objective Our aim was to describe the use of an east–west cheek‐based flap (horizontal advancement flap) to repair a surgical defect on the nose ala. Methods Benefits and limits of this surgical procedure are evaluated. Result The resulting S‐shaped scar was well‐camouflaged among the natural skin lines (melolabial fold and melonasal junction). No architectural distortion of the nose resulted from the procedure. Conclusion In selected patients with small‐to‐medium‐size defects of the nasal ala, the horizontal advancement flap is a simple, reliable and aesthetic reconstruction option. 相似文献